https://www.scmp.com/business/article/3332501/chinese-drug-developer-biokin-postpones-hong-kong-listing-citing-market-conditions?module=top_story&pgtype=subsection
Chinese drug developer Biokin postpones Hong Kong listing, citing ‘market conditions’ | South...
Nov 12, 2025 - Decision likely reflects ‘some pullback in risk appetite, with growth-stock share prices coming off their highs’, Morningstar analyst says.
hong kong listingchinesedrug
https://www.biopharmadive.com/news/abbvie-landos-acquire-deal-immune-crohns-colitis/711225/
AbbVie to buy immune drug developer Landos | BioPharma Dive
Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.
drug developerbiopharma dive